Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13544321 | 0.93 | ABL1 (0.38) | ABL1SRCTRPV1LRRK2KDR | |
| SCHEMBL13763402 | 0.84 | TRPV1 (0.46) | ABL1SRCTRPV1KDR | |
| SCHEMBL3591762 | 0.80 | KDR (0.43) | TRPV1KDRMAPTKDM4ENPC1 | |
| SCHEMBL3584801 | 0.80 | KIT (0.50) | ABL1SRCKITPIK3CAMTOR | |
| SCHEMBL3582343 | 0.79 | KDR (0.57) | TRPV1KDRMAPTKDM4ENPC1 | |
| SCHEMBL13544276 | 0.77 | KDR (0.43) | ABL1SRCTRPV1KDRMAPT | |
| SCHEMBL3585323 | 0.76 | LRRK2 (0.45) | TRPV1LRRK2MAPTRXFP1KDM4E | |
| SCHEMBL3582961 | 0.75 | TRPV1 (0.69) | TRPV1 | |
| SCHEMBL3588579 | 0.74 | RAB9A (0.47) | TRPV1LRRK2MAPTRXFP1KDM4E | |
| SCHEMBL3586739 | 0.72 | HSD11B1 (0.48) | TRPV1LRRK2MAPTRXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | claimed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | ABL1 3103/4885SRC 3118/4885TRPV1 1/4885 |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | ABL1 3092/4885SRC 2802/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.